Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

BioStock: Progress for Stayble Therapeutics in the second quarter

Stayble Therapeutics

The second quarter was an intense period with several important achievements for the Gothenburg-based pharmaceutical company Stayble Therapeutics. After a successful capital raise, the company can run the two ongoing studies with STA363 at the desired pace. According to the plan, the phase IIb study in degenerative disc disease will be completed in the second half of 2023. The company also looks forward to treating the first patient in the phase Ib study in herniated discs.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/08/progress-for-stayble-therapeutics-in-the-second-quarter/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.